FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
UroToday International Journal has seen a lot of changes over the years, and as we have grown and evolved with the times, we have continued to focus on accessible, informative content catering to our extensive urology readership. That being said, we knew it was time for some enhancement.
We recently debuted the improved UIJ website, with superior search functionality, an easy-to-navigate archive, and a host of other enhanced options to make each visit to the journal not just productive but enjoyable. We hope that once you’ve browsed our most recent issue, you’ll take a tour of the site to see our fresh, new face.
In this issue, Siami et al. discuss an effective and generally well-tolerated alternative administration method for intra-abdominal histrelin acetate implants in patients with advanced prostate cancer.
Rasmussen and team determine the results of a 60-person survey regarding the results of anticholinergic therapy on post-void dribbling. Their results suggest anticholinergic medications appear effective in treating PVD with efficacy similar to that of OAB.
Presented in their URO-RISK study, Mendive et al. investigate the epidemiological significance of urinary incontinence and overactive bladder in a primary care setting. They conclude that a higher level of health care be made available.
Elkoushy et al. compare and contrast three different lithotripters and their results during shock wave lithotripsy re-treatment. The big three—Storz, Siemens, and Philips—provide some interesting outcomes.
Al-Ba’adani and colleagues present their expertise in performing tubeless percutaneous nephrolithotomy as well as their diagnoses for indications, safety, and effectiveness.
We also present a variety of case reports, including acute penile prosthesis, ectopic kidney, and robotic partial nephrectomy.
With our new makeover comes a host of possibilities, and we hope that our dedicated readers, writers, and researchers get the most out of each and every article, CME, and case diagnosis available.